|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.95 USD | -1.21% |
|
-3.47% | -2.78% |
Company Valuation: Beam Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 4,611 | 5,327 | 2,692 | 2,159 | 1,974 | 2,660 | 2,660 | - |
| Change | - | 15.54% | -49.47% | -19.78% | -8.58% | 34.75% | 0% | - |
| Enterprise Value (EV) 1 | 4,318 | 4,367 | 1,613 | 969.4 | 1,974 | 1,373 | 1,768 | 1,498 |
| Change | - | 1.12% | -63.05% | -39.92% | 103.62% | -30.42% | 28.75% | -15.28% |
| P/E ratio | -19.5x | -13.8x | -9.47x | -15.8x | -5.41x | -6.3x | -5.82x | -5.87x |
| PBR | 15.5x | 6.19x | 3.66x | 2.14x | 2.83x | 2.33x | 3.75x | 3.35x |
| PEG | - | -0.4x | 0.3x | 0.3x | -0x | 0.95x | -0.7x | 6.21x |
| Capitalization / Revenue | 192,105x | 103x | 44.2x | 5.72x | 31.1x | 68.7x | 59.5x | 39.8x |
| EV / Revenue | 179,928x | 84.2x | 26.5x | 2.57x | 31.1x | 35.5x | 39.6x | 22.4x |
| EV / EBITDA | - | -11.3x | -4.97x | -6.2x | -5.01x | -2.92x | -3.52x | -2.84x |
| EV / EBIT | -32.5x | -11.1x | -4.77x | -5.49x | -4.75x | -2.78x | -3.28x | -2.61x |
| EV / FCF | -38.5x | -38.6x | -61.1x | -5.3x | -5.54x | -5.11x | -4.77x | -4.11x |
| FCF Yield | -2.6% | -2.59% | -1.64% | -18.9% | -18% | -19.6% | -21% | -24.4% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -4.19 | -5.77 | -4.13 | -1.72 | -4.58 | -4.277 | -4.633 | -4.589 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.024 | 51.84 | 60.92 | 377.7 | 63.52 | 38.7 | 44.67 | 66.8 |
| EBITDA 1 | - | -385 | -324.3 | -156.5 | -393.6 | -470.7 | -502.7 | -527.4 |
| EBIT 1 | -132.8 | -392.5 | -338.5 | -176.5 | -415.6 | -493.4 | -538.6 | -575 |
| Net income 1 | -195.9 | -370.6 | -289.1 | -132.5 | -376.7 | -402.5 | -493.3 | -536 |
| Net Debt 1 | -292.3 | -960.4 | -1,078 | -1,190 | - | -1,286 | -891.5 | -1,162 |
| Reference price 2 | 81.64 | 79.69 | 39.11 | 27.22 | 24.80 | 26.95 | 26.95 | 26.95 |
| Nbr of stocks (in thousands) | 56,474 | 66,849 | 68,821 | 79,326 | 79,592 | 98,693 | 98,693 | - |
| Announcement Date | 15/03/21 | 28/02/22 | 28/02/23 | 27/02/24 | 25/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.38x | 36.33x | -2.99x | -.--% | 2.69B | |
| 36.1x | 5.24x | 17.58x | 0.95% | 47.17B | |
| 106.93x | 6.85x | 68.55x | -.--% | 38.6B | |
| 61.08x | 12.47x | 34.89x | 0.31% | 34.53B | |
| 27.24x | 2.84x | 12.17x | -.--% | 32.68B | |
| -17.32x | 4944x | -16.15x | -.--% | 18.7B | |
| 35.83x | 5.79x | 26.3x | -.--% | 14.94B | |
| 25.82x | 2.11x | 9.46x | 0.94% | 14.13B | |
| -37.46x | 14.25x | -40.66x | -.--% | 13.73B | |
| Average | 25.76x | 558.88x | 12.13x | 0.25% | 24.13B | |
| Weighted average by Cap. | 40.86x | 432.40x | 21.81x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BEAM Stock
- Valuation Beam Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition